Neurogastrx Bags $45M, a New CEO and a HQ Move to the Greater Boston Area Post author:Sam Post published:January 3, 2018 Post category:BioPharma The Series A financing was co-led by 5AM Ventures, OrbiMed Advisors and venBio Partners. Source: BioSpace You Might Also Like FDA Calls Bay Area Zogenix's Dravet Syndrome Drug a Breakthrough February 5, 2018 KSQ Emerges With $76 Million and Will be Helmed by Former CEO October 1, 2017 <b>Kaleido Biosciences</b> Emerges From Stealth Mode With $65 Million and Will be Helmed by Fomer Cubist Exec September 17, 2017
<b>Kaleido Biosciences</b> Emerges From Stealth Mode With $65 Million and Will be Helmed by Fomer Cubist Exec September 17, 2017
